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Abstract
Background: Total skin electron irradiation (TSEI) is a special radiotherapy technique which has generally been
used for treating adult patients with mycosis fungoides. Recently, two infants presented with leukemia cutis
isolated to the skin requiring TSEI. This work discusses the commissioning and quality assurance (QA) methods for
implementing a modified Stanford technique using a rotating harness system to position sedated pediatric
patients treated with electrons to the total skin.
Methods and Results: Commissioning of pediatric TSEI consisted of absolute calibration, measurement of
dosimetric parameters, and subsequent verification in a pediatric patient sized cylindrical phantom using
radiographic film and optically stimulated luminance (OSL) dosimeters. The depth of dose penetration under TSEI
treatment condition was evaluated using radiographic film sandwiched in the phantom and demonstrated a 2 cm
penetration depth with the maximum dose located at the phantom surface. Dosimetry measurements on the
cylindrical phantom and in-vivo measurements from the patients suggested that, the factor relating the skin and
calibration point doses (i.e., the B-factor) was larger for the pediatric TSEI treatments as compared to adult TSEI
treatments. Custom made equipment, including a rotating plate and harness, was fabricated and added to a
standard total body irradiation stand and tested to facilitate patient setup under sedated condition. A pediatric TSEI
QA program, consisting of daily output, energy, flatness, and symmetry measurements as well as in-vivo dosimetry
verification for the first cycle was developed. With a long interval between pediatric TSEI cases, absolute dosimetry
was also repeated as part of the QA program. In-vivo dosimetry for the first two infants showed that a dose of ±
10% of the prescription dose can be achieved over the entire patient body.
Conclusion: Though pediatric leukemia cutis and the subsequent need for TSEI are rare, the ability to commission
the technique on a modified TBI stand is appealing for clinical implementation and has been successfully used for
the treatment of two pediatric patients at our institution.
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Background
Total skin electron irradiation (TSEI) is a special radio-
therapy technique which aims to deliver a uniform dose
to the entire skin of a patient while sparing all other
organs from a significant amount of radiation. TSEI has
historically been used for the treatment of cutaneous T-
cell lymphoma (mycosis fungoides), but has also been
extended for the treatment of other cutaneous diseases
such as Kaposi’s sarcoma and scleromyxodema [1-3].
Due to the ability to achieve therapeutic dose levels to
the skin with a rapid fall-offi nd o s eb e y o n das h a l l o w
depth to avoid bone marrow toxicity, electron beams
delivered to the total body in the energy range of 3-7
MeV (4-10 MeV at the accelerator beam exit window)
have been shown to be successful for treating these
superficial lesions. First proposed in the early 1950’s,
various TSEI treatment techniques have been evaluated
and clinically implemented [4-10], and a detailed techni-
cal report on the subject has been published for the
American Association of Physicists in Medicine by the
American Institute of Physics [11].
Recently, two pediatric patients with recurrent acute
myelogenous leukemia presenting with leukemia cutis
(LC) were treated at the University of Texas
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TSEI. LC is an extramedullary leukemia where neoplas-
tic leukocytes have infiltrated into the skin. Although
uncommon, this skin manifestation can occur with most
forms of leukemia. Patients typically present with multi-
ple raised skin nodules and plaques. The isolated skin
condition suggests treatment with superficial electron
beam irradiation to the total skin and has previously
been clinically described in case reports [12-15].
A particular challenge in implementing a clinical
pediatric TSEI program is how to deliver a uniform
dose to the total skin of a sedated infant. This report
describes the dosimetric commissioning and quality
assurance (QA) procedures for implementing a clinical
TSEI program for the treatment of LC in pediatric
patients using a modified Stanford technique [4,16,17].
The commissioning of fabricated setup equipment used
to hold sedated pediatric patients in a modified total
b o d yi r r a d i a t i o n( T B I )s t a n di sa l s op r e s e n t e d .T ot h e
best of our knowledge, this is the first report on the
commissioning and clinical implementation of pediatric
TSEI using this technique.
Methods
The pediatric TSEI technique described below is based
on a modified Stanford technique, which has been used
for treating adult TSEI patients at our institution. In
developing a pediatric TSEI program, the same beam
configuration of six dual-fields was adopted. Due to the
smaller size of pediatric patients and the sedation
requirement for consistent positioning, however, addi-
tional equipment and dosimetric commissioning mea-
surements were required. The following section
describes the measurements used in commissioning our
adult TSEI program and the further steps required for
commissioning and performing QA tests for pediatric
TSEI patients.
Dosimetric commissioning and quality assurance
Adult TSEI field flatness and calibration
At our institution, adult TSEI patients are treated with
six dual-fields (anterior, posterior, and four obliques)
using gantry angles of ± 20° from the horizontal axis.
These angles are used to achieve a uniform dose (±
10%) over a region of more than 170 cm while simulta-
neously reducing the total body dose from the mostly
forward peaked contaminant bremsstrahlung photons.
The combined beam profile, shown in Figure 1, was
measured at the surface of solid water stacks (1 mm
intrinsic ion chamber buildup) using an Exradin P11
parallel-plate ion chamber (Standard Imaging, Middle-
t o n ,W I )a tad i s t a n c eo f3 3 0c mS S Df r o maV a r i a n
Clinac 21EX linear accelerator (Varian Medical Systems,
Palo Alto, CA) operating under the high dose rate TSE
mode (6 MeV, 888 MU/min nominal dose rate). A 1.2
cm plexiglass scatter plate was placed 25 cm in front of
the patient to provide additional electron scattering and
to reduce the electron incident energy.
Absolute calibration of the machine output was per-
formed for a single dual-field beam, using an Exradin
P11 parallel-plate ion chamber under treatment condi-
tions (330 cm SSD, 36 × 36 cm
2 field size, 250° and
290° gantry angles) at a depth of dmax on the horizon-
tal central axis according to AAPM protocol [11]. The
parallel-plate chamber was first cross-calibrated
against a NIST-traceable PTW 31013 cylindrical ion
chamber (PTW, Hicksville, NY) in an 18 MeV elec-
tron beam, following AAPM TG-21 [18] and TG-51
[19] protocols.
The entire treatment was delivered to a Rando phan-
tom (The Phantom Laboratory, Salem, NY). Following
AAPM Report 23 [11], the multiplication factor (B-fac-
tor) for adult patients, which relates the treatment skin
dose (DS)w to the calibration point dose (DP)w,w a s
determined using OneDose MOSFETs (Sicel Technolo-
gies, Inc., Morrisville, NC) placed on the surface of the
Rando phantom and percent depth dose data. Concep-
tually, this factor represents the decrease in dose for
each single field due to the contribution from the two
adjacent fields. The B-factor was used to specify the
dose per field per treatment cycle and required monitor
units (MU) to patients, and was also used as the starting
point for MU calculations to deliver doses to a pediatric
patient sized phantom described below.
Phantom measurements for pediatric TSEI commissioning
Since the pediatric patient size is much smaller than the
adult patient, it is necessary to determine whether the
B-factor for the adult patient is applicable to the pedia-
tric patient. A custom made cylindrical acrylic phantom
of 20 cm diameter and 25 cm height was used for this
evaluation. Two aluminum oxide (Al2O3)M i c r o S t a r
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Figure 1 Combined beam profile at 330 cm SSD. The gantry was
directed at ± 20° from the horizontal.
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Page 2 of 7nanoDot™ optically stimulated luminescent (OSL) dosi-
meters (Landauer Inc., Glenwood, IL) were placed on
each of four locations (anterior, posterior, left lateral,
and right lateral) at the surface of the phantom and
aligned with the central axis. A surface dose of 50 cGy
was delivered by manually rotating the phantom at 60°
steps through each of the six TSEI positions. The
required number of MUs was calculated using the B-
factor for the adult patient. The dose received by the
OSL nanoDots were read out using a MicroStar OSL
reader with a luminescence-to-dose calibration curve
applied.
XV film was sandwiched in the cylindrical acrylic
phantom at mid-phantom height. The excess film was
cut in a darkroom so that the film edges conformed to
the circular surface of the phantom. 3 M Scotch black
duct tape was wrapped around the phantom over the
film edge to ensure the film was light-tight. The film
plane was aligned with the horizontal central axis hori-
zontal plane and a 50 cGy surface dose was delivered
using the same technique as described above. The film
was then developed and scanned using a Vidar VXR
Dosimetry Pro film digitizer (VIDAR Systems Corpora-
tion, Herndon, VA). RIT113V5.2 software (Radiological
Imaging Technology, Inc., Colorado Springs, CO) was
used to apply a calibration curve to assess the depth
dose distribution, dose profile, and isodose curves.
Treatment design
Equipment
In order to position sedated pediatric patients into the six
required angles required for TSEI, a rotating plate/harness
system was constructed and attached to a custom made
frame used for Total Body Irradiation (TBI) treatments
(Figure 2). A central bar was mounted on top of the TBI
frame and an aluminum rotating plate was attached to the
bar. Holes were drilled on the outer rim of the rotating
plate at 120 degrees increments to facilitate patient posi-
tioning at 60° interval for the 6 positions. A bolt is used to
index the rotating plate to the top central bar for each dif-
ferent position to ensure the positioning accuracy. The
entire plate can be moved along the central bar, which is
parallel to the beam axis, to maintain a constant patient to
spoiler distance of 25 cm at the central beam axis for each
position over the course of the treatment.
A custom made harness was sewn to hold the patient
vertically. The harness only covers the trunk of the
patient body, leaving arms and legs uncovered. The har-
ness attaches to the rotating plate with four belts which
loop through carabiner clips. The lengths of the belts
(a) (b)
rotating plate 
harness 
carabiner clips 
Figure 2 The patient in treatment positions for (a) PA and (b) RAO locations.
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Page 3 of 7were constructed such that the patient umbilicus is cen-
tered along the horizontal beam axis. The harness was
made from a single layer cloth to minimize the attenua-
tion of the electron beam yet maintain enough strength
to support an infant. To ensure patient safety during
treatment, the strength of the harness was verified by
placing weights inside the harness while hanging on the
rotating plate for at least one hour.
Treatment procedure
Two patients (17 months and 12 months old) have been
treated since commissioning this pediatric TSEI technique.
Each patient was scheduled to receive 16 Gy over the
entire treatment course for 8 cycles as described in case
reports [13,14]. Each cycle consists of two treatment days
with three dual-fields each: AP, LPO, RPO on the first day
and PA, LAO, RAO on the second day. During treatment
days, morning machine output quality assurance was per-
formed using the high dose rate TSE delivery mode using
a Daily QA3 detector array (Sun Nuclear Corporation,
Melbourne, FL) to verify output consistency.
Prior to each treatment, the stand was moved into a
preset position and the source-to-spoiler distance was
measured to ensure the correct stand position. The
patient was anesthetized and placed within the harness
while on a gurney. The patient was monitored for
hemodynamic status, pulse oximetry, and nasal end tidal
carbon dioxide levels during the entire treatment. The
patient was carefully lifted into place while the harness
belts were clipped onto the carabiners attached to the
rotating plate. The patient’sh e a dw a se i t h e rs u p p o r t e d
by a piece of acrylic plate placed opposite of the beam
or taped in place to the harness belts. Patient arms were
positioned in similar positions as for adult TSEI patients
using Velcro strips which were looped around the TBI
frame and attached to a Styrofoam pad taped to the
patient’s hand opposite of the beam (Figure 2). After the
patient AP position was set, the distance from the
patient to the spoiler was measured, and the rotating
plate was moved along the bars of the TBI stand to the
desired 25 cm spoiler-to-patient distance. The required
number of MUs was delivered and then the patient was
rotated to each posterior oblique position for each sub-
sequent delivery to complete the first half of the cycle.
As part of routine quality assurance tests, OSL dosi-
meters were placed on the patient’ss k i na tm u l t i p l e
locations. Doses for the first two days of treatment were
measured and combined to give the total dose delivered
during one cycle, and this was compared against the
prescription dose of 200 cGy per cycle. Based on the
OSL measurements, the B-factor and the required MUs
were adjusted if needed in order to meet our absolute
dose and dose uniformity criteria.
Results
Phantom measurements for pediatric TSEI commissioning
Two nanoDots were placed on each of four locations on
the cylindrical acrylic phantom and uniformly irradiated
to a nominal dose of 50 cGy, based on the adult TSEI
B-factor of 2.414, using the six dual-field technique.
Each nanoDot was read out 3 times and the average of
the 3 readings is shown in Table 1.
T h ed o s ed e l i v e r e dt ot h es u r f a c eo ft h e2 0c md i a -
meter phantom was measured to be 53.7 cGy on aver-
age at the four locations around the phantom
periphery, 7.3% higher than the nominally delivered
dose. Given the intrinsic 5% accuracy of the OSL dosi-
meters, the dose uniformity requirement, and the fact
that these measurements were not patient specific, the
B-factor was not adjusted for subsequent patient MU
calculations.
While the OSL dosimeters were used for absolute
dose measurements, film was used for relative dose
measurements because a batch specific calibration curve
and carefully controlled development conditions were
not used. Figure 3a shows the dose distribution on a
central axial slice of the 20 cm diameter cylindrical
phantom measured by KODAK X-OMAT V (XV) film
following the delivery of the MUs calculated to deliver
50 cGy. Two orthogonal lines were drawn using RIT
software and the profiles are shown in Figure 3b. Based
on the dose profile of the film, it can be seen that the
periphery of the film was uniformly irradiated from the
degraded 6 MeV electron beams. The penetration of
electrons after the spoiler has a maximum range of
approximately 2 cm, with the maximum dose occurring
at the surface of the phantom. The cold surface dose
artifact on the right-hand side of the horizontal profile
Table 1 OSL detector measured dose on 20 cm diameter cylindrical phantom following delivery of a prescribed 50
cGy
OSL Detector Location NanoDot 1 Dose (cGy) NanoDot 2 Dose (cGy) Average Dose (cGy) % Diff from Prescription
AP 54.3 53.3 53.8 7.6
Lt Lat 53.5 54.4 54.0 8.0
PA 53.9 53.1 53.5 7.0
Rt Lat 54.5 52.4 53.4 6.8
Average 53.7 7.3
Bao et al. Radiation Oncology 2012, 7:40
http://www.ro-journal.com/content/7/1/40
Page 4 of 7is believed to be caused by misalignment of the film
edge with the cylindrical phantom edge. Perfect align-
ment was difficult to obtain when cutting and matching
the film with the phantom in a dark-room.
Patient in-vivo dosimetry
During the first two treatment days (first cycle) of the
first pediatric TSEI patient, patient specific in-vivo dosi-
metry using OSL detectors was performed for different
locations on the body surface to verify dose calculations
and the B-factor. The resulting dose measurements are
summarized in Table 2. The average dose was 222.2
cGy over all measured locations, 11.1% higher on aver-
age than the prescription dose. This value was consis-
tent with the 7.3% higher dose measured on the
cylindrical phantom, thus the value of the B-factor was
increased by 10% (from 2.414 to 2.655) and the MUs
prescribed for each beam were correspondingly
decreased by 10%. Due to the smaller diameter of the
20 cm cylindrical phantom and pediatric patients, it is
reasonable that the B-factor increases compared to the
adult TSEI technique. For the six dual-field beam
arrangement, the dose contribution at any one location
is primarily from three of the six dual-fields. For exam-
ple, the dose contribution to the umbilicus point is pri-
marily from the AP, LAO and RAO beams. The AP
beam will contribute the same amount of dose to the
umbilicus point regardless of the patient size, but for a
smaller diameter phantom or patient at the same SSD,
the two oblique beams will contribute more dose to the
umbilicus point, resulting in a higher B-factor. This
inverse relationship of B-factor with patient diameter
has been reported previously [20].
Following adjustment of the MUs, in-vivo dosimetry
using OSL detectors was repeated as a second check on
selected locations of the patient during the second cycle
(days 3 and 4). Of the five locations measured, the aver-
aged dose was 201.9 cGy, which was 1.0% higher than
the prescription dose and within our accepted tolerance
(Table 3). Therefore the new B-factor and the calculated
MUs were used for the remainder of the treatment
course.
For the second pediatric TSEI patient, the adjusted B-
factor determined from phantom and in-vivo measure-
ments in the first patient was used for MU calculations.
In-vivo dosimetry was performed as in the previous
patient as part of patient-specific TSEI QA. The average
dose determined by the OSL detectors was 198.3 cGy,
0.8% lower than the prescription. Based on these results,
no adjustment was made to the dose calculations or
patient setup. However, with this patient, individual
regions including the top of the head and the inner
thighs exceeded our ± 10% dose uniformity criteria.
After discussing with the ain’s physician, an electron
boost was concurrently administered to the top of the
(a) (b) 
Figure 3 Film measurement for the composite TSEI beam.( a)
An XV film was uniformly irradiated with 50 cGy dose and (b) two
orthogonal profiles indicates the dose penetration of the TSEI beam.
Table 2 OSL detector dose measurements for cycle one of first patient
OSL Detector
Location
AP + LPO + RPO Day 1 Dose
(cGy)
PA + LAO + RAO Day 2 Dose
(cGy)
Total Dose
(cGy)
% Diff from
Prescription
Forehead 106.2 119.1 225.3 12.7
Posterior of head 152.1 96.2 248.3 24.2
Sternum 78.9 136.9 215.8 7.9
Posterior of sternum 137.8 85.9 223.7 11.9
Umbilicus 80.5 132.7 213.2 6.6
Posterior of Umbilicus 146.9 78.7 225.6 12.8
Left thigh 75.8 139.1 214.9 7.5
Posterior Left Thigh 145.9 81.5 227.4 13.7
Right thigh 77.1 133.7 210.8 5.4
Posterior Right Thigh 130.0 86.5 216.5 8.3
Right Foot 84.6 141.6 226.2 13.1
Bottom of Right Foot 135.9 82.6 218.5 9.3
Average 222.2 11.1
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half of the treatment course based on under dosage of
this region.
Discussion
In this work we present the commissioning and quality
assurance processes used to successfully implement a
pediatric TSEI program at UTSW. With this modified
Stanford technique, the sedated pediatric patient is
secured by a custom made harness and rotational sys-
tem attached to a common TBI stand. Though pediatric
leukemia cutis and the subsequent need for TSEI are
rare, the ability to commission the technique on a modi-
fied TBI stand is appealing for clinical implementation.
To the best of our knowledge this is the first complete
description of the commissioning and QA of pediatric
TSEI using a modified Stanford technique. Rubin et al.
[12] use a similar pediatric TSEI technique for the treat-
ment of acute monoblastic leukemia; however, it is pre-
sented as a medical case report with an incomplete
description of the irradiation technique and the com-
missioning and QA methods. Pepek et al. [13] also pre-
sent a medical case report for the treatment of leukemia
cutis in pediatric patients. In this work they provide a
brief description of the irradiation technique, which is
based on a rotating platform at extended distances. The
p e d i a t r i cp a t i e n t sw e r eo fa g ew h e r et h e yw e r ea b l et o
stand on their own in the required positions over the
course of the treatment, thus removing the need for
sedation and a rotating harness system. Earley et al. [7]
describe, to date, the most complete description of the
commissioning of a pediatric TSEI technique for the
treatment of a sedated acute myelocytic leukemia
patient. In this technique, the sedated patient is placed
on a platform that is carried to the floor for AP and PA
beams and the treatment couch for oblique beams (with
the gantry moved to different angles). Beam profiles
were acquired at a 200 cm distance for 6 MeV electrons
to assess uniformity. From the authors’ description, it
seems the rotating harness system and irradiation tech-
nique described in our work would facilitate a faster
total treatment time without having to move a patient
platform in unison with an oxygen airway, IVs, and
other lines for different beam positions.
Although commissioning showed overall surface dose
uniformity within ± 10% in the plane perpendicular to
the central axis for an adult patient’s dimensions, there
are many locations which could possibly exceed this
uniformity criterion. Due primarily to surface irregulari-
ties, this has also been observed in patients treated by
TSEI for mycosis fungoides. Surface cavities can receive
less dose than flat or convex surfaces, while higher
doses may occur in areas with body protrusions [21,22].
With the patient setup described in this work, in-vivo
dosimetry demonstrated that under dose regions can
occur when the skin is shielded by other body parts
(inner thigh and leg regions), when the skin is shielded
by patient vital sign monitoring equipment (beneath the
blood pressure cuff), and at the top of the head. The
inner thigh region underdose may be improved with the
use of additional straps to separate the legs; however, a
boost to the perineum region may still be needed at the
discretion of the physician. In both UTSW clinical
cases, every attempt was made to move oxygen tube and
monitoring wires out of the treatment fields and away
from the patient. The position of the blood pressure
cuff was moved throughout the course of treatment to
average out the shielding effect. As recommended in
AAPM Report No. 23 [11], the use of boost fields
required clinical judgment. Based on in-vivo dosimetry,
the physician elected for a 6 MeV electron boost to the
top of the head for the second patient with a 1 cm
bolus since this region was under dosed during TSEI
and this was the location of the isolated skin lesions.
When performing in-vivo dosimetry measurements to
verify that the prescribed dose is delivered correctly and
confirm dose uniformity, the choice of detector is impor-
tant to consider. Thermoluminescent dosimeters have
been the most commonly used for TSEI treatments due
to the small volume minimizing the effect of dose gradi-
ents across the dosimeter. OSL dosimeters have recently
been introduced for clinical dose measurements and have
been implemented in clinical TSEI programs [23]. OSL
dosimeters were used for in-vivo measurements due to
Table 3 OSL detector dose measurements for cycle two of first patient for reduced MUs
OSL Detector
Location
AP + LPO + RPO Day 3 Dose
(cGy)
PA + LAO + RAO Day 4 Dose
(cGy)
Total Dose
(cGy)
% Diff from
Prescription
Forehead 96.1 117.2 213.3 6.6
Posterior of Head 121.9 84 205.9 3.0
Umbilicus 79.1 117.3 196.3 18
Posterior of Umbilicus 125.6 72.6 198.2 09
Back of Right Hand 70.5 125.3 195.7 21
Average 201.9 1.0
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reader system.
Patient safety is of utmost important over the course
of treatment and was of primary consideration in the
commissioning process. It is crucial for the sedated
patient in the harness system to remain in the same
position while the treatment team is outside of the
vault. During commissioning, filled water jugs were
placed in the harness system to demonstrate structural
integrity. Velcro straps as well as paper tape were on
hand in abundance to set a consistent position. At every
treatment, a team including an anesthesiologist, nurse,
medical physicist, and radiation therapist were present
to secure the patient, monitor the patient, verify treat-
ment settings and setup, and deliver the required radia-
tion dose. In addition to in-vivo dosimetry, machine QA
procedures were implemented and performed on each
treatment day to verify proper operation in TSEI mode.
This consisted of checks for output, energy, symmetry,
and flatness constancy. Due to the infrequent use of this
treatment technique it is important, as part of the QA
protocol, to verify any changes in the system over time
which would affect the patient dose, including the abso-
lute output calibration and B-factor. At our clinic, the
second pediatric TSEI case for LC occurred approxi-
mately one year following the first case. Prior to the
first treatment day of the second pediatric case, a cali-
brated parallel plate ionization chamber was used for
absolute dosimetry in TSEI mode and the output for
this mode was adjusted to the value used for initial
commissioning.
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